These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33469828)

  • 1. Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.
    Xu Y; Ren Y; Li X; Xu W; Wang X; Duan Y; Liu Y; Zhang X; Tian DC
    Neurotherapeutics; 2021 Apr; 18(2):868-877. PubMed ID: 33469828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD.
    Carnero Contentti E; Delgado-García G; Criniti J; López PA; Pettinicchi JP; Cristiano E; Miguez J; Correa-Díaz EP; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Tkachuk V; Caride A; Rojas JI
    Front Immunol; 2021; 12():628024. PubMed ID: 33717149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.
    Mealy MA; Mossburg SE; Kim SH; Messina S; Borisow N; Lopez-Gonzalez R; Ospina JP; Scheel M; Yeshokumar AK; Awad A; Leite MI; Arango JJ; Paul F; Palace J; Kim HJ; Levy M
    Mult Scler Relat Disord; 2019 Feb; 28():64-68. PubMed ID: 30554040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder.
    Bonnan M; Debeugny S; Mejdoubi M; Cabre P
    Mult Scler; 2020 Apr; 26(4):468-475. PubMed ID: 30843448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
    Aungsumart S; Apiwattanakul M
    Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
    Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
    Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease.
    Murchison A; Kitley J; Leite MI; Küker W; Palace J
    J Neurol Sci; 2015 Aug; 355(1-2):49-53. PubMed ID: 26026944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Antunes Barreira A; Armas E; Chiganer E; de Aquino Cruz C; Di Pace JL; Hryb JP; Lavigne Moreira C; Lessa C; Molina O; Perassolo M; Soto A; Caride A
    Spinal Cord; 2018 Oct; 56(10):949-954. PubMed ID: 29789706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders.
    Pan J; Zhu R; Lin J; Li X; Xia J
    Mult Scler Relat Disord; 2022 Feb; 58():103513. PubMed ID: 35038646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders.
    Hu H; You X; Ye J
    Mult Scler Relat Disord; 2018 Apr; 21():78-83. PubMed ID: 29499441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
    Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
    BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of transverse myelitis associated with systemic lupus erythematosus.
    Zhang S; Wang Z; Zhao J; Wu DI; Li J; Wang Q; Su J; Xu D; Wang Y; Li M; Zeng X
    Lupus; 2020 Apr; 29(4):389-397. PubMed ID: 32054395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients.
    You X; Yan L; Li X; Pang Y; Guo X; Ye J; Hu H
    Mult Scler Relat Disord; 2019 Jan; 27():254-259. PubMed ID: 30419511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India.
    Gupta S; Rehani V; Acharya R; Purohit P; Anadure R; Ahmad F; Soni R; Gupta A; Hiremath R
    Mult Scler Relat Disord; 2021 Jan; 47():102616. PubMed ID: 33166808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
    Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
    Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
    Demuth S; Guillaume M; Bourre B; Ciron J; Zephir H; Sirejacob Y; Kerbrat A; Lebrun-Frenay C; Papeix C; Michel L; Laplaud D; Vukusic S; Maillart E; Cohen M; Audoin B; Marignier R; Collongues N;
    J Neuroinflammation; 2022 Mar; 19(1):62. PubMed ID: 35236386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study.
    Xie H; Zhao Y; Pan C; Zhang J; Zhou Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    BMC Neurol; 2021 Oct; 21(1):389. PubMed ID: 34625035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.